Related Experiment Video
Updated: Jul 14, 2026

Real-Time Polymerase Chain Reaction-Based Detection and Quantification of Hepatitis B Virus DNA
Published on: December 15, 2023
Hepatitis B core-related antigen as a multifaceted biomarker in chronic hepatitis B: implications for immune activity
Kwon Yong Tak1, Seok Hwan Kim1, Myeong Jun Song2
1Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Background/Aims:
Hepatitis B core-related antigen (HBcrAg) reflects both serum hepatitis B virus (HBV) DNA and intrahepatic covalently closed circular DNA activity, offering potential advantages over conventional biomarkers in monitoring chronic hepatitis B (CHB). This study evaluated the clinical utility of HBcrAg across immune phases and its prognostic value for hepatocellular carcinoma (HCC).
Methods:
In this retrospective study, 281 CHB patients from Daejeon St. Mary's Hospital (September 2022-July 2024) were classified into HBV phases. HBcrAg was quantified using the ultrasensitive iTACT-HBcrAg assay. HBcrAg level was compared across HBV phases, HCC presence, and patient characteristics.
Results:
HBcrAg levels varied significantly across immune phases, with an AUC of 0.97 for HBeAg(+) IA vs. IT, and 0.83 for HBeAg(-) IA vs. II. In HBeAg(-) IA, HBcrAg ≥ 3.8 LogU/mL was associated with higher HCC prevalence at AUC 0.69, while in HBeAg(+) IA, ≥ 4.9 LogU/mL was the optimal cut-off at AUC 0.71. In HBeAg(-) II, HBcrAg < 3.8 LogU/mL was linked to the absence of HCC. HBcrAg correlated inversely with age (r = -0.31, p < 0.0001), while the relationship with fibrosis severity differed according to HBeAg status. In multivariate analysis, HBcrAg remained independently associated with HCC (OR 1.64, p = 0.002). Residual HBcrAg positivity was observed in patients with HBsAg loss.
Conclusion:
HBcrAg is a robust biomarker capturing both virologic and immunologic activity in CHB, with additional prognostic value for HCC, particularly in IA phases. It may complement or surpass conventional markers in phase classification and risk stratification.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test